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TGF-β1 promotes expression of 
fibrosis-related genes through the 
induction of histone variant H3.3 
and histone chaperone HIRA
Toshihiro Shindo1, Shigehiro Doi1, Ayumu Nakashima  1, Kensuke Sasaki1, Koji Arihiro2 & 
Takao Masaki1
Renal fibrosis is a histological manifestation that occurs in almost every type of chronic kidney disease. 
Histone variant H3.3 and its chaperone, histone cell cycle regulation defective homolog A (HIRA), 
serve as epigenetic marks that regulate transcriptional activity. In this study, we assessed the roles 
of histone H3.3 and HIRA in unilateral ureteral-obstruction (UUO) mice. In UUO mice, the levels of 
histone H3.3 and HIRA were significantly upregulated in the kidneys. These upregulated levels were 
decreased by a TGF-β1 neutralizing antibody. TGF-β1 induced histone H3.3 and HIRA expression in 
vitro via a Smad3-dependent pathway in normal rat kidney (NRK)−52E cells. Additionally, knockdown 
of HIRA expression decreased histone H3.3 expression and fibrogenesis in NRK-52E cells after TGF-
β1 stimulation. Chromatin immunoprecipitation analysis revealed that promoters of fibrosis-related 
genes were immunoprecipitated with both histone H3.3 and HIRA in NRK-52E cells. Lastly, in human 
kidney biopsies from patients diagnosed with IgA nephropathy, histone H3.3 and HIRA immunostaining 
correlated positively with areas of fibrosis and estimated glomerular filtration rate. In conclusion, TGF-
β1 induces expression of histone H3.3 and HIRA, which regulates expression of fibrosis-related genes.
Chronic kidney disease (CKD) is estimated to occur in 13–15% of the population in developed countries1,2 
and it exerts a substantial socioeconomic burden worldwide. Importantly, progressive CKD not only results in 
end-stage kidney disease (ESKD) but also increases mortality from any cause3–9, particularly from cardiovascular 
disease6–9. To suppress the progression of CKD, inhibitors of the renin-angiotensin-aldosterone system have been 
developed10. However, these treatments have limited effects and many patients finally succumb to irreversible 
ESKD and require dialysis or kidney transplantation.
Irrespective of the initial causes, renal fibrosis occurs in ESKD11. Pathologically, renal fibrosis is characterized 
by excessive proliferation of α-smooth muscle actin (α-SMA)-positive myofibroblasts and overproduction of 
extracellular matrix (ECM), which eventually leads to renal failure12,13. Among a number of cytokines, trans-
forming growth factor (TGF)-β1 is a fundamental agent in the progression of renal fibrosis14,15. Recently, we 
demonstrated that TGF-β1-induced histone H3 lysine 4 monomethylation (H3K4me1) promotes the transcrip-
tional activity of genes involved in fibrosis through the induction of SET domain–containing lysine methyltrans-
ferase 7/9 (SET7/9)16. However, SET7/9 possibly affects all histone tails of histone H3; therefore, the epigenetic 
mechanism by which TGF-β1 specifically regulates transcriptional activity of fibrosis-related genes is not fully 
understood.
In chromatin, histones exist as an octamer that contains two molecules of each core histone, H2A, H2B, H3, 
and H417. Histone variants are incorporated by histone chaperones in place of canonical histones and function as 
a transcriptional landmark. The histone variant, H3.3, is specifically enriched at transcriptionally active genes18–21, 
and histone cell cycle regulation defective homolog A (HIRA) is the specific histone chaperone of histone H3.322–24. 
Renal fibrosis is considered to be a state in which fibrosis-related genes are activated by TGF-β1, raising the pos-
sibility that TGF-β1-regulated histone variants contribute to renal fibrosis16. Moreover, a recent study revealed 
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that histone H3.3 overlaps with H3K4me1 and serves as an enhancer of active genes25. These findings led us to 
the hypothesis that TGF-β1-induced HIRA plays a role in renal fibrosis through incorporation of histone H3.3.
In this study, we used ureter obstruction (UUO) model mice, a well-established rodent model of 
TGF-β1-mediated renal fibrosis26. We show that TGF-β1 induces histone H3.3 and HIRA via a Smad3-dependent 
pathway. We also demonstrate that HIRA is involved in the induction of histone H3.3 and in TGF-β1-induced 
α-SMA expression in vitro. Furthermore, chromatin immunoprecipitation (ChIP) analysis revealed that TGF-β1 
increases the immunoprecipitation of histone H3.3 and HIRA on promoters of fibrosis-related genes. Finally, 
renal expression of histone H3.3 and HIRA correlated with fibrotic areas and estimated glomerular filtration rate 
(eGFR) in renal biopsies from IgA nephropathy (IgAN) patients. These findings suggest that TGF-β1 promotes 
renal fibrosis through the induction of histone H3.3 and HIRA.
Results
Histone H3.3 and HIRA expression increase in mouse kidney after UUO. To understand the role of 
histone H3.3 and HIRA in the progression of tubulointerstitial fibrosis, we first examined the gene expression and 
protein levels of histone H3.3 and HIRA in UUO mice. As shown in Fig. 1A,B, expression of H3f3a and H3f3b, 
encoding histone H3.3, and Hira was remarkably increased on day 7 in UUO mice compared with sham controls. 
Western blot analysis revealed that the protein levels of histone H3.3 and HIRA were increased in UUO mice 
compared with sham controls, consistent with the increases in mRNA expression (Fig. 1C,D).
Histone H3.3 and HIRA expression is positively regulated by TGF-β1 in UUO mice and in renal 
cells. TGF-β1 is a main mediator of renal fibrosis in UUO mice27. HE and Masson’s trichrome staining showed 
histological changes in UUO mice with or without administration of neutralizing TGF-β1 antibody (Fig. 2A). 
We then examined the regulation of histone H3.3 and HIRA by TGF-β1 in vivo and in vitro. There was a signifi-
cant increase in H3f3a, H3f3b and Hira mRNA levels after treatment with mouse IgG1 in UUO mice compared 
Figure 1. Histone H3.3 and HIRA are up-regulated in the kidney after obstructive injury. (A) Histone H3.3 
(H3f3a and H3f3b) and (B) Hira mRNA levels were determined by quantitative real-time polymerase chain 
reaction (qRT-PCR) 7 days after sham or UUO surgery. UUO-induced (C) histone H3.3 and (D) HIRA protein 
levels were confirmed by western blotting. Histone H3 for histone H3.3 and β-Actin for HIRA were used as 
internal controls. Data are means ± S.D. *P < 0.05, (t test; n = 5 mice per group).
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with sham operated mice. Administration of neutralizing TGF-β1 antibody suppressed mRNA levels of H3f3a, 
H3f3b and Hira in UUO mice28 (Fig. 2B,C). Similar results were observed for histone H3.3 and HIRA protein 
levels (Fig. 2D). Immunohistochemical staining for histone H3.3 and HIRA was predominantly enhanced in 
the nuclei of tubular epithelial and glomerular cells in UUO mice, and was abrogated by neutralizing TGF-β1 
antibody (Fig. 2E). For in vitro studies we used normal rat kidney (NRK)−52E cells, a rat kidney tubular epi-
thelial cell line, and NRK-49F cells, a rat kidney interstitial fibroblast cell line. TGF-β1 at doses ≥1.0 ng/mL 
Figure 2. TGF-β1 induces histone H3.3 and HIRA expression and injection of neutralizing TGF-β1 antibody 
reduces histone H3.3 and HIRA expression after UUO. UUO mice were treated with mouse immunoglobulin 
G1 (IgG1) or neutralizing TGF-β1 antibody (TGF-β1-Ab). (A) Images of HE and Masson’s trichrome staining 
show histological change in UUO mice with control IgG1 or TGF-β1-Ab. (B) mRNA levels of histone H3.3 
(H3f3a and H3f3b) and (C) Hira were determined in kidneys by qRT-PCR. (D) Representative western blot 
analysis of histone H3.3 and HIRA is shown. Histone H3 for histone H3.3 and β-Actin for HIRA were used as 
internal controls. Relative levels of expression are shown in the lower panel. (E) Images of histone H3.3 and 
HIRA staining demonstrating the levels of histone H3.3 and HIRA after treatment with control IgG1 or TGF-
β1-Ab. Bar = 100 μm. Data are means ± S.D. *P < 0.05, (one-way ANOVA followed by the post hoc t test with 
Bonferroni correction; n = 5 mice per group).
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significantly upregulated histone H3.3 and HIRA protein levels in both cell lines compared with vehicle-treated 
control (Fig. 3A,B). The same effect was observed 6 hours after stimulation with 1.0 ng/mL TGF-β1 (Fig. 3C,D).
TGF-β1 induces histone H3.3 and HIRA expression via Smad3 activation. TGF-β1 is an important 
mediator during the progression of renal fibrosis through the activation of several signaling pathways, including 
the Smad3 pathway29. We examined whether TGF-β1-induced phosphorylated Smad3 (p-Smad3) is involved in 
the regulation of histone H3.3 and HIRA expression. NRK-52E cells were treated with small interfering RNA 
(siRNA) of Smad3 (si-Smad3) or negative control siRNA (si-Neg). After 30 minutes or 24 hours of TGF-β1 stimu-
lation at dose of 1.0 ng/mL, total transfected cells were collected and analyzed. Rat H3f3a primers were not com-
mercially available; therefore, we investigated H3f3b and Hira mRNA levels and protein levels of histone H3.3 and 
HIRA in NRK-52E cells. H3f3b and Hira mRNA levels were significantly decreased in NRK-52E cells treated with 
si-Smad3 (Fig. 4A). Similar results were observed for histone H3.3 and HIRA protein levels (Fig. 4B,C). Likewise, 
si-Smad3 treatment significantly reduced the levels of Smad3 and TGF-β1-induced p-Smad3 (Fig. 4D,E).
Knockdown of HIRA attenuates histone H3.3 and TGF-β1-induced fibrogenesis in rat kidney 
tubular epithelial cells. Next, we used siRNA targeting Hira (si-HIRA) or negative control siRNA (si-Neg) 
to investigate whether HIRA promotes fibrogenesis in NRK-52E cells. The effect of si-HIRA in NRK-52E cells was 
confirmed by reduced HIRA mRNA and protein levels 24 hours after transfection relative to si-Neg with or with-
out 1.0 ng/mL TGF-β1 stimulation (Fig. 5A). Treatment with si-HIRA inhibited TGF-β1-induction of histone 
H3.3 mRNA and protein levels (Fig. 5B). Levels of α-SMA (Acta2) and collagen1 (Col1a1) mRNA were very low 
in the groups without TGF-β1 stimulation, and they progressively increased in the si-Neg and TGF-β1-treated 
group. In contrast, mRNA levels of Acta2 and Col1a1 were significantly decreased in the si-HIRA treated group. 
Figure 3. TGF-β1 induces histone H3.3 and HIRA expression in renal epithelial and fibroblast cells. 
Representative western blotting analysis shows the levels of histone H3.3 and HIRA proteins in TGF-β1-
stimulated NRK-52E and NRK-49F cells at various doses (time; 24 hours) for (A) histone H3.3 and (B) HIRA, 
and time points (TGF-β1; 1.0 ng/mL) for (C) histone H3.3 and (D) HIRA. Histone H3 for histone H3.3 and 
β-Actin for HIRA were used as internal controls. Expression levels were compared with vehicle-treated control. 
Relative levels of expression are shown in the lower panel. Data are means ± S.D. *P < 0.05, **P < 0.01, (one-
way ANOVA followed by Dunnett’s post hoc test based on vehicle-treated controls; n = 5 samples per group).
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Figure 4. TGF-β1-induced histone H3.3 and HIRA expression is suppressed by knockdown of Smad3 in 
NRK-52E cells. NRK-52E cells were treated with Smad3 siRNA (si-Smad3) or negative control (si-Neg) 
oligonucleotides. (A) histone H3.3 (H3f3b) and Hira mRNA levels were determined by qRT-PCR in stimulated 
NRK-52E cells with or without TGF-β1 (1.0 ng/mL, 24 hours). Representative western blot analysis for (B) 
histone H3.3, (C) HIRA, (D) Smad3, and (E) phosphorylated Smad3 (p-Smad3) in stimulated NRK-52E cells 
with or without TGF-β1 (1.0 ng/mL, 30 minutes or 24 hours). Because p-Smad3 reaches a peak 30 minutes after 
TGF-β1 stimulation, this time point was only used in p-Smad3 experiments. Histone H3 for histone H3.3, and 
β-Actin for HIRA, Smad3, and p-Smad were used as internal controls. Relative levels of expression are shown in 
the lower panel. Data are means ± S.D. *P < 0.05, **P < 0.01, (one-way ANOVA followed by the post hoc t test 
with Bonferroni correction; n = 5 samples per group).
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In addition, western blotting showed that si-HIRA but not si-Neg attenuated α-SMA protein expression in 
TGF-β1-treated cells (Fig. 5C).
TGF-β1 regulates access of fibrosis-related gene promoters to histone H3.3 and HIRA. To 
assess whether TGF-β1 alters the transcriptional activity of H3.3 and HIRA-regulated genes, we conducted ChIP 
assays in NRK-52E cells. TGF-β1 increased histone H3.3 and HIRA immunoprecipitation of Col1a1, connective 
tissue growth factor (Ctgf), plasminogen activator inhibitor-1 (Pai1), and Acta2 gene promoters. Neutralization 
of TGF-β1 counteracted TGF-β1-induced expression of these genes (Fig. 6).
Figure 5. Knockdown of HIRA in NRK-52E cells inhibits TGF-β1-induced fibrogenesis by suppressing 
histone H3.3 expression. NRK-52E cells were treated with Hira siRNA (si-HIRA) or negative control (si-Neg) 
oligonucleotides. (A) Hira, (B) histone H3.3 (H3f3b), (C) α-SMA (Acta2), and collagen1 (Colla1) mRNA levels 
were determined by qRT-PCR in stimulated NRK-52E cells with or without TGF-β1 (1.0 ng/mL, 24 hours). 
Representative western blot analysis for (A) HIRA, (B) histone H3.3 and (C) α-SMA. Histone H3 for histone 
H3.3 and β-Actin for HIRA and α-SMA were used as internal controls. Relative levels of expression are in the 
lower panel. Data are means ± S.D. *P < 0.05, **P < 0.01, (one-way ANOVA followed by the post hoc t test with 
Bonferroni correction; n = 5 samples per group).
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HIRA expression correlates with histone H3.3 expression, tubulointerstitial fibrosis and eGFR 
in kidney biopsies from IgAN patients. To examine the clinical significance of histone H3.3 and HIRA 
in tubulointerstitial fibrosis, we performed immunohistochemistry for histone H3.3 and HIRA on IgAN patient 
Figure 6. HIRA co-localizes with histone H3.3 at activated promoters of fibrotic genes in NRK-52E cells. 
Treatment with neutralizing TGF-β1 antibody (2.0 μg/mL) was performed at the same time as TGF-β1 (1.0 ng/
mL) stimulation. Chromatin immunoprecipitation (ChIP) analysis of the binding of (A) histone H3.3 and (B) 
HIRA proteins to Col1a1, Ctgf, Pai1 and Acta2 promoters in NRK-52E cells is shown. Immunoprecipitated 
DNA and input DNA were subjected to qPCR. Results were normalized to input DNA and rabbit 
immunoglobulin G (IgG) was used as a negative control. Data are means ± S.D. *P < 0.05, **P < 0.01, (one-way 
ANOVA followed by the post hoc t test with Bonferroni correction; n = 5 samples per group).
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biopsies (n = 28). All patients underwent renal biopsy at Hiroshima University Hospital for the first time between 
April, 2008 and December, 2010. The average clinical values of the patients were as follows: 36 (31–41) years of 
age, body mass index was 21 (20–24) kg/m2, creatinine clearance was 91 (78–109) mL/minute, eGFR was 75 (59–
89) mL/minute/1.73 m2, and urinary protein excretion was 0.81 ± 0.78 g/24 hours. We show the details of clinical 
characteristics related to renal function in Supplemental Table 1. As shown in Fig. 7, immunohistochemistry and 
histology of biopsies showed that HIRA expression correlated positively with histone H3.3 expression (ρ = 0.46, 
P = 0.015). In terms of fibrosis, Masson’s trichrome-positive area correlated positively with histone H3.3 (ρ = 0.52, 
P = 0.004) and HIRA expression (ρ = 0.39, P = 0.038), and α-SMA expression was correlated with histone H3.3 
(ρ = 0.42, P = 0.027) and HIRA expression (ρ = 0.42, P = 0.026). With respect to clinical values, eGFR correlated 
inversely with histone H3.3 (ρ = −0.68, P = 0.008) and HIRA expression (ρ = −0.53, P = 0.014), but urinary pro-
tein excretion did not show significant correlation with expression of histone H3.3 (ρ = 0.19, P = 0.34) or HIRA 
(ρ = −0.11, P = 0.56).
Discussion
Here, we have shown five new findings. First, expression of histone H3.3 and HIRA increases in a mouse model of 
renal fibrosis induced by UUO. Second, the TGF-β1-Smad3 pathway regulates the expression of histone H3.3 and 
HIRA. Third, inhibition of HIRA suppresses TGF-β1-induced fibrogenesis along with a decrease in histone H3.3 
expression. Fourth, both HIRA and histone H3.3 immunoprecipitate with promotors of genes involved in fibro-
sis, such as Col1a1, Ctgf, Pai1 and Acta2. Finally, histone H3.3 and HIRA expression correlates with not only the 
degree of fibrosis but also with eGFR in IgAN patient kidneys. This study provides insights into the mechanism 
by which histone H3.3 and HIRA are involved in TGF-β1-mediated fibrogenesis, and indicates that this histone 
variant and its chaperone are therapeutic targets for CKD.
Epigenetic regulation of gene expression, for example DNA methylation, histone acetylation and histone 
methylation, are implicated in renal fibrosis30–32. DNA methylation contributes to renal fibrosis, and inhibition of 
DNA methyltransferase 1 suppresses UUO-induced renal fibrosis33, while histone deacetylase inhibitors show an 
anti-fibrotic effect in mice34. Histone methylation also contributes to renal fibrosis through induction of histone 
methyltransferases, such as SET7/9 and G9a16,35. In this study, we demonstrated that expression of histone variant 
H3.3 and its specific chaperone HIRA were increased in UUO mice. We also showed that levels of histone H3.3 
and HIRA in renal biopsies are positively correlated with fibrotic area in IgAN patients. These findings indicate 
that, in addition to DNA methylation and histone modifications, a histone variant also participates in the pro-
gression of renal fibrosis.
We have demonstrated that HIRA plays an essential role in the expression of histone H3.3 in 
TGF-β1-stimulated NRK-52E cells. An important aspect of histone variant dynamics relates to the mechanism 
of their incorporation, which involves histone chaperones and can modulate cell fate and the stability of gene 
expression programs. Histone chaperones regulate the complicated steps folding histones together with DNA 
to form correctly assembled nucleosomes36–39. Replicative histones such as histone H3.1 and H3.2, which are 
the main components of histone H3, are replicated during S phase in the cell cycle, and are deposited in a DNA 
synthesis-coupled manner40. In contrast, histone H3.3 is incorporated into sites of increased transcriptional 
activity, independently of both replication and cell cycle41–43. We also demonstrated that TGF-β1 increases the 
transcriptional activity of fibrosis-related genes, and that promoters of these genes are immunoprecipitated with 
histone H3.3 and HIRA. These findings indicate that histone H3.3 is incorporated into transcriptionally active 
fibrotic genes by TGF-β1-induced HIRA.
Histone variants function as transcriptional landmarks in response to external stimuli and to maintain 
networks of gene expression in cooperation with histone modifications44. Histone variants are involved in 
highly-diversified biological processes45,46. Among these, histone H3.3 is related to specific cancer types, includ-
ing pediatric high-grade glioblastoma and certain types of bone tumors47. In addition, we confirmed that knock-
down of HIRA with siRNA reduced TGF-β1-induced α-SMA expression in rat kidney tubular epithelial cells. 
Because increased expression of α-SMA-positive myofibroblasts is a hallmark of renal fibrosis12, HIRA is consid-
ered to participate in the development of renal fibrosis through histone H3.3 induction48.
TGF-β1 is a crucial mediator of renal fibrosis progression. In fact, a number of studies show that inhibition 
of the TGF-β1 signaling pathway ameliorates renal fibrosis49–51. At the molecular level, TGF-β1 not only induces 
transformation of kidney tubular epithelial cells into myofibroblasts but also promotes production of ECM pro-
teins in response to tissue damage15. In this study, we showed that UUO-induced histone H3.3 and HIRA expres-
sion is suppressed by a TGF-β1-neutralizing antibody, indicating that UUO-mediated TGF-β1 contributes to 
histone H3.3 and HIRA expression in mice. Moreover, we have demonstrated that phosphorylation of Smad3 is 
involved with histone H3.3 and HIRA expression. Although p-Smad3 is a transcription factor that upregulates 
fibrotic genes, TGF-β1-Smad3 signaling also promotes transcriptional activity of these genes29.
In this study, si-HIRA did not affect p-Smad3 levels in TGF-β1-stimulated NRK-52E cells (Supplemental 
Figure S1), suggesting that HIRA is a downstream effector of Smad3. Additionally, we examined mouse kidneys, 
human kidney biopsies from actual patients, and rat kidney tubular epithelial cells. UUO is as an established 
model of progressive renal fibrosis26. We used UUO mice on day 7 in this study, because severe fibrosis is observed 
on day 7 after UUO52. Another reason is that we cannot observe molecular changes after the development of fibro-
sis is complete. A number of other studies have investigated renal fibrosis in UUO mice on day 753–55. Moreover, 
we selected NRK52E cells which are representative and reliable for the investigation of TGF-β1-mediated fibrotic 
changes56. Activation of the TGF-β1-Smad3 pathway is observed during progression of fibrosis in UUO mice and 
NRK-52E cells, as reported by numerous studies57–59. Taken together, our data from UUO mice, rat kidney cells 
and human biopsy samples indicate that histone H3.3 and HIRA are implicated in TGF-β1-induced renal fibrosis.
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Figure 7. HIRA expression correlates with the expression of histone H3.3, the degree of fibrosis and estimated 
glomerular filtration rate (eGFR) in human kidney biopsy specimens (n = 28). (A) Representative images of 
histone H3.3, HIRA, Masson’s trichrome staining and α-SMA demonstrate that levels of histone H3.3, HIRA, 
and the size of fibrotic areas increase with the decline of eGFR in patients with IgA nephropathy (IgAN). 
Columns show images from the same patient. (B) HIRA expression correlated positively with histone H3.3 
expression (ρ = 0.46, P = 0.015), Masson’s trichrome-positive areas (ρ = 0.39, P = 0.038), α-SMA levels (ρ = 0.42, 
P = 0.026) and eGFR (ρ = −0.53, P = 0.014). Histone H3.3 expression was positively correlated with Masson’s 
trichrome-positive areas (ρ = 0.52, P = 0.004), α-SMA levels (ρ = 0.42, P = 0.027) and eGFR (ρ = −0.68, 
P = 0.008). Spearman’s correlation coefficient test was used. Bar = 50 μm. The Japanese GFR equation based on 
serum creatinine was used to determine eGFR. eGFR (mL/minute/1.73 m2) = 194 × Scr−1.094 × Age−0.287 × 0.739 
(if female).
www.nature.com/scientificreports/
1 0SCieNTifiC RepoRTs |  (2018) 8:14060  | DOI:10.1038/s41598-018-32518-8
Although we showed that inhibition of HIRA expression suppresses TGF-β1-induced α-SMA expression in 
tubular epithelial cells, the role of HIRA in the progression of renal fibrosis in vivo remains unclear. Hira knock-
out mice exhibit embryonic lethality60; therefore, further studies with a small molecular inhibitor are needed to 
assess the potential of HIRA as a therapeutic target for renal fibrosis. In addition, we showed that TGF-β1 induces 
histone H3.3 and HIRA expression at both mRNA and protein levels, but these changes, although statistically 
significant, are of relatively small magnitude. However, as shown in Supplemental Figure S2, protein expression 
is expressed by the formula, target protein/loading control; therefore, a large value for the internal control, rather 
than a small degree of difference, contributes to the small level in this study. We also showed that neutralizing 
TGF-β1 antibody and si-Smad3 suppress histone H3.3 and HIRA expression, and that si-HIRA inhibits histone 
H3.3 and TGF-β1-induced fibrotic change. These findings provide the evidence that TGF-β1 induces histone 
H3.3 and HIRA expression even though the changes are small in magnitude.
In summary, we showed that histone H3.3 and HIRA expression is increased in UUO mice. We also demon-
strated that TGF-β1 upregulates expression of both histone H3.3 and HIRA via a Smad3-dependent pathway. 
Inhibition of HIRA suppresses not only expression of histone H3.3 but also fibrotic changes in renal epithe-
lial cells. Furthermore, histone H3.3 and HIRA immunoprecipitate with fibrosis-associated promoters. Last, we 
demonstrated that the expression of histone H3.3 and HIRA is correlated with fibrotic areas and eGFR in patients 
with IgAN. To the best of our knowledge, no small molecule drug exists that targets HIRA. However, from the 
data presented here, we suggest that inhibition of HIRA is a promising therapeutic strategy for the treatment of 
renal fibrosis.
Concise Methods
Animals. Eight-week-old male C57BL/6 mice weighting about 25 g were obtained from Charles River 
Laboratories Japan (Yokohama, Japan). The Institutional Animal Care and Use Committee at Hiroshima 
University (Hiroshima, Japan) approved all animal experiments (Permit Number: A15-28), and the experiments 
were performed according to the National Institutes of Health Guidelines on the Use of Laboratory Animals. Mice 
were randomly assigned to either UUO (n = 5) or sham (n = 5) groups. UUO was performed under general anes-
thesia (medetomidine, midazolam, and butorphanol) as previously described61,62. To investigate the early phase 
of renal fibrosis progression, mice were sacrificed on day 3 or day 7 after UUO and renal tissues were harvested.
Mouse treatments. To investigate the expression pathway of histone H3.3 and HIRA in UUO mice, neutral-
izing anti-TGF-β1 antibody (1D11, 1.5 mg/kg, R&D Systems, Minneapolis, MN) or normal mouse IgG1 (11711, 
1.5 mg/kg, R&D Systems) was administered immediately after UUO by intraperitoneal injection. The same treat-
ments were repeated every 48 hours until mice were sacrificed, as previously described63. Sham-operated mice 
were administered same volume of vehicle intraperitoneally.
Cell Culture and treatments. NRK-52E and NRK-49F cells were purchased from the American Type 
Culture Collection (Manassas, VA). These cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 5% fetal bovine serum (FBS) and penicillin/streptomycin. Cells were washed and growth-arrested 
for 24 hours in DMEM including 0.1% FBS before each stimulation. NRK-52E and NRK-49F cells were stimu-
lated with TGF-β1 at the indicated doses and times. NRK-52E cells were treated with Smad3 siRNA (Invitrogen, 
Carlsbad, CA) using Lipofectamine 2000 Reagent (Invitrogen) in accordance with the product protocol. After 
incubation with transfection complexes for 6 hours, the medium was changed, and the cells were stimulated with 
1.0 ng/mL TGF-β1 (R&D Systems) for 24 hours. For Hira siRNA (Invitrogen), incubation with transfection com-
plexes was for 24 hours. To counteract the effects of TGF-β1 on cultured cells, subconfluent cells were incubated 
with 2.0 μg/mL anti-TGF-β1 antibody (Abcam, Cambridge, UK) at the same time as TGF-β1 stimulation. Cells 
were then exposed to TGF-β1 (1.0 ng/mL) with anti-TGF-β1 antibody for 24 hours.
RNA extraction and quantitative real-time RT-PCR (qPCR). RNA extraction and qPCR were per-
formed as previously described using an ABI 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, 
CA)64. Predesigned gene-specific oligonucleotide primers and probes for Acta2 (assay ID: Mm00725412_s1), 
Col1a1 (assay ID: Mm00801666_g1), H3f3a (assay ID: Mm01612808_g1), H3f3b (assay ID: Mm00787223_s1; 
assay ID: Rn00821572_g1), and Hira (assay ID: Mm00468902_m1; assay ID: Rn01405424_m1) were purchased 
from TaqMan Gene Expression Assays (Applied Biosystems). The level of Glyceraldehyde 3-phosphate dehydro-
genase (Gapdh) mRNA was used as an internal control.
Western blot analysis. Renal tissues or cells seeded in six-well dishes were lysed in 2% SDS sample buffer 
and sonicated using a Taitec ultrasonic homogenizer VP-050 at 20% power for 30 seconds. Western blot analysis 
was performed as described previously65. Primary antibodies used in this study were as follows: anti-histone H3.3 
(Abcam), anti-p-Smad3 (Cell Signaling Technology, Danvers, MA), anti-Smad3 (Cell Signaling Technology), 
anti-HIRA (Cell Signaling Technology), anti-histone H3 (Cell Signaling Technology), anti-α-SMA antibody 
(Sigma-Aldrich, St Louis, MO) and anti-β-Actin (Sigma-Aldrich). Horseradish peroxidase-conjugated goat 
anti-rabbit immunoglobulin G antibody (Dako, Glostrup, Denmark) or goat anti-mouse immunoglobulin G 
antibody (Dako) were used as Secondary antibodies. Signals were detected by the SuperSignal West Dura or Pico 
system (Thermo Fisher, Rockford, IL), and the intensity of each band was quantified by ImageJ software (version 
1.48p; National Institutes of Health, Bethesda, MD, USA).
Histology and immunohistochemistry. Histological and immunohistochemical staining of tissue was 
performed as previously described66. Rabbit polyclonal anti-histone H3.3 antibody (Abcam), rabbit polyclonal 
anti-HIRA antibody (Abcam), and mouse monoclonal anti-α- SMA antibody (Sigma-Aldrich) were used as pri-
mary antibodies. Areas of histone H3.3, HIRA, Masson’s trichrome staining or α-SMA were assessed in five 
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random fields (×200 magnification) captured by a digital camera and analyzed using ImageJ. Human kidney 
specimens were obtained from 28 patients diagnosed with IgAN following renal biopsy at Hiroshima University 
Hospital between April 2008 and December 2010. The demographic and clinical characteristics of patients are 
shown in Supplemental Table 1. The research was approved by the Ethics Committee of Hiroshima University 
(H-2087), and was accordance with relevant guidelines. Informed consent was obtained from each patient.
ChIP assays. ChIP assays of Col1a1, Ctgf, Pai1, and Acta2 were performed using a ChIP assay kit 
(Millipore, Temecula, CA) as previously described67. The resulting solutions from NRK-52E cells were incu-
bated overnight at 4 °C with anti-histone H3.3 antibody (Abcam) or anti-HIRA antibody (Abcam). DNA was 
purified using the QIAquick PCR Purification Kit (Qiagen, Valencia, CA). DNA samples were subjected to 
qPCR using gene-specific primers as follows:68 forward 5′-GGCTGGAGAAAGGTGGGTCT-3′ and reverse 
5′-CCCAGGTATGCAGGGTAGGA-3′ were used for Col1a1, forward 5′-ATCAGGAAGGGTGCGAA 
GAG-3′ and reverse 5′-TCCACATTCCTCCGTCTGAA-3′ were used for Ctgf, forward 5′-gacaatATGTGCCC 
TGTGATTGtC-3′ and reverse 5′-AGGCTGCTCTACTGGTCCTTGC-3′ were used for Pai1 as described previously32, 
and forward 5′-GTAACATAGGCTGGTGAATCCTG-3′ and reverse 5′-GAGTGATCATTTTATGGAAGCCAC-3′ 
were used for Acta2 as described previously69.
Statistical analysis. The results are shown as the mean ± S.D. We used the t test for comparisons between 
two groups and one-way analysis of variance (ANOVA) followed by the post hoc test using Dunnett’s test or the t 
test with Bonferroni correction for multiple group comparisons. Correlation was calculated using the Spearman 
correlation coefficient. The presence of a normal distribution was evaluated by the Shapiro-Wilk test. Data with a 
normal distribution are expressed as the mean ± S.D., and other variables are expressed as the median (25th-75th 
percentiles). P < 0.05 was considered statistically significant.
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